Back to news

Tango Therapeutics Slides as Pipeline Reprioritization Overshadows Trial Update

Investivoq PriceTracker

Tango Therapeutics (TNGX) is down 18% today. Here is some analysis on what might have caused this price movement.

Analysis: The selloff appears tied less to the headline clinical data and more to the broader strategic update that came with it. This could be because investors focused on Tango’s decision to narrow its research efforts, stop certain preclinical activities, and cut staff even as the company highlighted encouraging pancreatic cancer results.

Details:

  • Tango disclosed updated Phase 1/2 data showing an 82% objective response rate, median progression-free survival not yet reached, and an 88% nine-month progression-free survival rate in 22 evaluable previously treated pancreatic cancer patients receiving vopimetostat plus daraxonrasib.
  • The company said it plans to launch a global registrational Phase 3 study in first-half 2027 for front-line MTAP-deleted pancreatic cancer, which shifts the story toward a longer and more resource-intensive development path.
  • In the same 8-K, Tango approved a strategic reprioritization to focus on PRMT5 programs and deprioritize novel target discovery, while stopping certain preclinical and research activities.
  • Tango also said it intends to reduce its workforce by about 14%, with most of the cuts coming from research, a move that can signal both cost discipline and a narrower pipeline outlook.

    • Sources:

    Tango Therapeutics ([tangotx.gcs-web.com](https://tangotx.gcs-web.com/news-releases/news-release-details/tango-presents-promising-results-phase-12-study-vopimetostat-and)), SEC ([tangotx.gcs-web.com](https://tangotx.gcs-web.com/node/9956/html)), Investivoq ([Investivoq.com](https://www.Investivoq.com/news/Why%2BTango%2BTherapeutics%2BShares%2BAre%2BFalling%2BToday?utm_source=openai))

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $TNGX Insider Trading Activity

    TNGX Insider Trades

    $TNGX insiders have traded $TNGX stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales.

    Here’s a breakdown of recent trading of $TNGX stock by insiders over the last 6 months:

    • ADAM CRYSTAL (President, R&D) has made 0 purchases and 11 sales selling 162,000 shares for an estimated $3,989,799.
    • JESSICA NEWCOMB (Principal Accounting Officer) has made 0 purchases and 3 sales selling 8,200 shares for an estimated $198,612.

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    EARLY ACCESS
    Receive TNGX Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $TNGX Hedge Fund Activity

    We have seen 163 institutional investors add shares of $TNGX stock to their portfolio, and 75 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • ADAGE CAPITAL PARTNERS GP, L.L.C. removed 7,209,485 shares (-56.3%) from their portfolio in Q2 2026, for an estimated $225,368,501
    • NEXTECH INVEST LTD. removed 5,533,980 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $172,992,214
    • PRICE T ROWE ASSOCIATES INC /MD/ added 5,459,427 shares (+613.8%) to their portfolio in Q2 2026, for an estimated $170,661,688
    • GOLDMAN SACHS GROUP INC added 4,904,228 shares (+96.6%) to their portfolio in Q2 2026, for an estimated $153,306,167
    • WOODLINE PARTNERS LP removed 3,999,446 shares (-50.0%) from their portfolio in Q2 2026, for an estimated $125,022,681
    • BLACKROCK, INC. added 3,690,399 shares (+42.2%) to their portfolio in Q2 2026, for an estimated $115,361,872
    • SEVEN FLEET CAPITAL MANAGEMENT LP added 2,726,132 shares (+543.0%) to their portfolio in Q2 2026, for an estimated $85,218,886

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $TNGX Analyst Ratings

    Wall Street analysts have issued reports on $TNGX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

    Here are some recent analyst ratings:

    • Leerink Partners issued a "Outperform" rating on 06/08/2026

    To track analyst ratings and price targets for $TNGX, check out Investivoq's $TNGX forecast page.

    $TNGX Price Targets

    Multiple analysts have issued price targets for $TNGX recently. We have seen 8 analysts offer price targets for $TNGX in the last 6 months, with a median target of $43.0.

    Here are some recent targets:

    • John Newman from Canaccord Genuity set a target price of $46.0 on 06/29/2026
    • Maury Raycroft from Jefferies set a target price of $60.0 on 06/26/2026
    • Robert Burns from HC Wainwright & Co. set a target price of $66.0 on 06/09/2026
    • Andrew Berens from Leerink Partners set a target price of $69.0 on 06/08/2026
    • Kelsey Goodwin from Piper Sandler set a target price of $24.0 on 05/15/2026
    • Joseph Catanzaro from Mizuho set a target price of $30.0 on 05/15/2026
    • Robert Driscoll from Wedbush set a target price of $33.0 on 05/14/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.